This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.

Moderna shares surge after it says experimental mRNA cancer treatment passed key test

Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.

PBS NewsHourYesterday

Published by CurrentWire Aug 21, 2026 at 3:31 PM ET · First coverage Aug 20, 2026 at 10:49 AM ET

Compiled by CurrentWire News Desk

Summary based on reporting from PBS NewsHour.

Moderna shares surge after it says experimental mRNA cancer treatment passed key test

Read the full report at PBS NewsHour

X Facebook LinkedIn Email

Automated coverage analysis

Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.

Source mix

1 independent editorial domain

What coverage breadth measures

Coverage

1 publication is covering this story.

PBS NewsHourTier A
Moderna shares surge after it says experimental mRNA cancer treatment passed key test(opens original report in a new tab)Yesterday

How CurrentWire compiled this story

PBS NewsHour (www.pbs.org), a Tier A publisher, filed this report on Aug 20, 2026 at 10:49 AM ET. CurrentWire published this page 29 hours later, on Aug 21, 2026 at 3:31 PM ET.

Filed under Health · International · News.

CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.